Medicare Part D vs. the exchanges: with so many similarities, why have the two programs fared so differently?
Health Care Current | June 12, 2018
While health plans and PBMs have generally fared well in Part D, it has often been a different story with the exchanges. Here’s why.
Digital R&D: Transforming the future of clinical development
Biopharma R&D has changed the face of disease management over the years. Yet many in the field admit that clinical development has fallen behind in adopting digital technologies, which have the potential to change how research organizations can engage with patients, innovate in patient care, and execute processes to drive efficiencies. While digital transformation is a complex, resource-intensive, and lengthy undertaking, the rewards are well worth the effort.
How biopharma companies are bolstering R&D pipeline through deal-making
Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. But when choosing from the three main options open to them—licensing, mergers and acquisitions, and joint ventures—what factors should they examine, and do deal types differ in the ways they accelerate development and deliver long-term value?